Adherence and resource use among psoriasis patients treated with biologics
- PMID: 30142007
- DOI: 10.1080/14737167.2018.1512408
Adherence and resource use among psoriasis patients treated with biologics
Abstract
Introduction: The emergence of immune-modulating drugs such as biologics has altered the treatment landscape for psoriasis. However, their use presents high financial costs to patients and healthcare systems. Patient demographic and socioeconomic status may influence adherence to biologic medications and usage of healthcare resources.
Areas covered: We performed a systematic literature review to summarize the available evidence pertaining to biologic medication adherence and resource use. PubMed was searched using the terms 'psoriasis and adherence' and 'psoriasis biologics resource use.'
Expert commentary: Psoriasis patients utilize many healthcare resources. Adherence rates are typically higher for biologics than for other psoriasis treatment categories. However, adherence rates are still suboptimal.
Keywords: Adherence; biologics; drug cost; healthcare resource use; psoriasis.
Similar articles
-
Medication adherence and health care costs associated with biologics in Medicaid-enrolled patients with psoriasis.J Dermatolog Treat. 2006;17(5):294-301. doi: 10.1080/09546630600954594. J Dermatolog Treat. 2006. PMID: 17092860
-
Healthcare resource utilization and costs among psoriasis patients treated with biologics, overall and by disease severity.J Med Econ. 2018 Aug;21(8):745-754. doi: 10.1080/13696998.2018.1472097. Epub 2018 May 22. J Med Econ. 2018. PMID: 29718756
-
Adherence to biologics in patients with psoriasis.Expert Rev Clin Immunol. 2018 Feb;14(2):155-161. doi: 10.1080/1744666X.2018.1427065. Epub 2018 Jan 16. Expert Rev Clin Immunol. 2018. PMID: 29327643
-
Biologics in pediatric psoriasis - efficacy and safety.Expert Opin Drug Saf. 2018 Jan;17(1):9-16. doi: 10.1080/14740338.2018.1391787. Epub 2017 Oct 30. Expert Opin Drug Saf. 2018. PMID: 29022425 Review.
-
Use of biologics for psoriasis in Central and Eastern European countries.J Eur Acad Dermatol Venereol. 2015 Nov;29(11):2222-30. doi: 10.1111/jdv.13222. Epub 2015 Sep 14. J Eur Acad Dermatol Venereol. 2015. PMID: 26370506 Review.
Cited by
-
Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study.Rheumatology (Oxford). 2022 Apr 11;61(4):1589-1599. doi: 10.1093/rheumatology/keab522. Rheumatology (Oxford). 2022. PMID: 34244706 Free PMC article.
-
A Review of the Clinical Trial Landscape in Psoriasis: An Update for Clinicians.Dermatol Ther (Heidelb). 2022 Dec;12(12):2715-2730. doi: 10.1007/s13555-022-00840-9. Epub 2022 Nov 1. Dermatol Ther (Heidelb). 2022. PMID: 36319883 Free PMC article. Review.
-
Relationship between serum trough levels and efficacy of brodalumab from a post hoc exploratory analysis of a Japanese study in patients with plaque psoriasis.J Dermatol. 2021 Mar;48(3):324-333. doi: 10.1111/1346-8138.15690. Epub 2020 Nov 8. J Dermatol. 2021. PMID: 33161605 Free PMC article.
-
Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic Dermatitis.Am J Clin Dermatol. 2022 Jan;23(1):1-11. doi: 10.1007/s40257-021-00639-y. Epub 2021 Oct 26. Am J Clin Dermatol. 2022. PMID: 34699031 Free PMC article.
-
Adherence and Persistence to Biological Drugs for Psoriasis: Systematic Review with Meta-Analysis.J Clin Med. 2022 Mar 9;11(6):1506. doi: 10.3390/jcm11061506. J Clin Med. 2022. PMID: 35329831 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical